论文部分内容阅读
普伐他汀（I）是一种降血脂药，它通过抑制HMGCOA还原酶活性和调节肝内LDL受体而发挥其药理作用。据报道，健康人服用本品后有相当部分的I通过非酶途径转化成为主要代谢物3a-羟基异普伐他汀（Ⅱ），这一转化主要在胃内低PH环境中进行。Ⅱ对上述还原酶的抑制活性仅相当于I的1／4
Pravastatin (I) is a hypolipidemic agent that exerts its pharmacological effects by inhibiting the activity of HMGCOA reductase and regulating intrahepatic LDL receptors. It is reported that healthy people taking this product after a considerable part of I by non-enzymatic pathway into the main metabolite 3a-hydroxy-pravastatin (II), this conversion is mainly in the low-pH environment for the stomach. Ⅱ inhibitory activity of the above reductase is only equivalent to 1/4 of I.